Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients.
about
Strong opioids for cancer painSymbiotic relationship of pharmacogenetics and drugs of abuse.Integrating palliative care with intensive care for critically ill patients with lung cancer.Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly IndividualsChronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site.Morphine disrupts interleukin-23 (IL-23)/IL-17-mediated pulmonary mucosal host defense against Streptococcus pneumoniae infection.The role of morphine glucuronides in cancer pain.Opioid rotation for cancer pain: rationale and clinical aspects.Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronideMorphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway.The pharmacology of mu analgesics: from patients to genes.The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Morphine inhibits murine dendritic cell IL-23 production by modulating Toll-like receptor 2 and Nod2 signaling.Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study.Morphine-6-glucuronide (M6G) for postoperative pain relief.Pharmacogenetic treatments for drug addiction: alcohol and opiates.Mu opioids and their receptors: evolution of a concept.Integration of palliative care in chronic critical illness managementA systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.The use of opioids in cancer patients with renal impairment-a systematic review.Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion.Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories.When oral morphine fails in cancer pain: the role of the alternative routes.The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein.Comment: opioid-induced muscle activity.Adult cancer pain.The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.
P2860
Q28353103-3A543131-9347-4458-BD17-50BD098AA9FDQ28476270-BE703FF2-7493-45D1-9CB8-F66EA0AE59B1Q30427793-0865C9B8-1938-4DB9-B4DF-FF1ABEB9EA61Q30828459-5A1D3689-580D-42AE-945F-76310C61333FQ33597153-7F41FF90-7A00-4B2A-A4D9-B6515B437CF5Q33613877-12A37546-EB6E-4D75-BD6F-5A90D21EE29EQ33727191-409A5F0C-564A-494C-8E41-DE5B8D153AE1Q33765787-DC89D8F3-DB3D-4ADC-9DDF-587D97669925Q33891564-A198896C-CAF0-417C-85D2-A95B91EB785CQ34033506-2950D575-6372-4BFA-BFA7-BCBFA30D041EQ34333349-5AD7771E-341C-48C5-AF81-B0F7D1DAD97EQ34580479-E73B6AE6-CFED-4AC9-B6DB-2679B12EA5A3Q34635638-A8772E72-4643-458B-9FE0-4EF45C5000B0Q34695622-2848D7DB-706C-4A08-BBCF-057B04257E5CQ35823710-DF97AD24-B973-4245-B150-4132501FD1D4Q36942294-98D9D351-1D2C-4CA4-996E-EB275BC04157Q37201611-EB52EC51-1E66-46B2-8FDE-434156219329Q37236111-375AC104-D215-4880-B00B-945C95C92437Q37342206-1C12E9D1-E640-4549-B5B1-570243B082DFQ37895002-C7181B23-208D-42F0-A90B-6D45E6DE92FCQ38981738-CDCFA526-F964-44B9-9FD3-A2834A8E9483Q39395812-01E9D4F5-E904-484B-BBE2-91658F95424DQ39405158-B91B18D7-D413-4B48-9132-07C8E2CFFC37Q42538403-4ECA5194-3A0F-4EFF-94D9-777ACAB5CA71Q43070533-A36B39C6-889B-4890-9FAE-1360BC45CE59Q43243208-96D275E3-6B39-4628-B28F-10D3C9D4E1CFQ43968416-3FC08B2A-57FE-4E27-9649-369014F9018FQ44210260-5AD31F32-8835-49A7-832B-9A1C16138B0CQ44343641-DBB75733-477E-4CA1-BBDC-FF9EA70966D1Q44426953-0A686C93-2488-4756-A301-7484CC657688Q47693272-FEA60A0A-47F9-480A-A0AA-F0AAD0279560
P2860
Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Morphine-6-glucuronide concent ...... : a survey in cancer patients.
@en
Morphine-6-glucuronide concent ...... : a survey in cancer patients.
@nl
type
label
Morphine-6-glucuronide concent ...... : a survey in cancer patients.
@en
Morphine-6-glucuronide concent ...... : a survey in cancer patients.
@nl
prefLabel
Morphine-6-glucuronide concent ...... : a survey in cancer patients.
@en
Morphine-6-glucuronide concent ...... : a survey in cancer patients.
@nl
P2093
P1433
P1476
Morphine-6-glucuronide concent ...... : a survey in cancer patients.
@en
P2093
C E Inturrisi
H T Thaler
R K Portenoy
P356
10.1016/0304-3959(94)00148-8
P407
P577
1995-04-01T00:00:00Z